This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Geron's cancer screening patent rejected as non-patentable under Indian law

By Freny Patel ( March 24, 2026, 01:49 GMT | Insight) -- A cancer screening patent from US-based biotechnology company Geron Corp. was rejected as non-patentable by the Delhi High Court in a ruling that emphasized India’s strict patent law and dismissed the relevance of foreign patent approvals.Geron Corp., a US-based biotechnology company, has failed to secure a patent in India for a specialized cancer screening method, despite obtaining corresponding patents in the US, Europe and Japan....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login